Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort

Végh, Zsuzsanna; Burisch, Johan; Pedersen, Natalia; Kaimakliotis, Ioannis; Ďuricová, Dana; Bortlík, Martin; Avnstrøm, Søren; Vinding, Kristoffer K.; Olsen, J; Nielsen, K R; Katsanos, K.H.; Tsianos, Epameinondas V.; Lakatos, László; Schwartz, Doron; Odes, Selwyn; Lupinacci, G.; Padova, A. De; Jonaitis, Laimas Virginijus; Kupčinskas, Limas; Turcan, Svetlana; Tighineanu, O.; Mihu, Ion; Barros, Louisa; Magro, Fernando; Lazăr, Daniela; Goldiş, Adrian; Fernández, Alberto; Hernández, Vicent; Niewiadomski, Olga; Bell, Sally; Langholz, Ebbe; Munkholm, Pia; Lakatos, Péter L.; EpiCom-group,

doi:10.1016/j.crohns.2014.06.004

Cited by 85 publications

(79 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, Crohn's disease has been reported worldwide, but the incidence and prevalence also appear to be lower in Asia and the Middle East. 29 Overall, we do believe that epidemiological figures of EoE will soon catch up with Crohn's disease, with similar and even higher prevalence rates than that of Crohn's disease likely expected for EoE in the next 10-20 years if the current epidemiologic trends persist. 27 In line with previous findings by Dellon et al, 20 we corroborated that the prevalence of EoE steadily increases from adolescence and peaks in the age group between 34 and 45 years old, sharply decreasing after 45 years old.…”

Section: Discussionmentioning

confidence: 99%

Rising incidence and prevalence of adult eosinophilic esophagitis in midwestern Spain (2007–2016)

Molina–Infante

Gonzalez-Cordero

Ferreira-Nossa

et al. 2017

United European Gastroenterology Journal

View full text Add to dashboard Cite

Objectives: Epidemiologic studies on eosinophilic esophagitis (EoE) are scarce and patient responders to proton pump inhibitor (PPI) therapy have usually been excluded. We aimed to evaluate population-based incidence rates, prevalence and trends in adult EoE over the past decade, including responders to PPI therapy. Methods: We conducted an analysis of a prospectively established case registry in the health area of Cáceres, located in midwestern Spain. From the first EoE case diagnosed in 2007, endoscopy and pathology reports up to December 2016 were manually reviewed. A baseline diagnosis of EoE was confirmed upon symptoms of esophageal dysfunction (dysphagia/food impaction) and esophageal eosinophilia 15 eos/HPF. All patients were re-evaluated on PPI therapy during follow-up. Results: A total of 137 patients were diagnosed with EoE during the study period, of whom 63 (46%) achieved clinicohistologic remission on PPI therapy. The prevalence of autoimmune disorders was low. Mean incidence rate was 8.09 new cases/100,000 inhabitants/year, increasing to 9.95 during the last lustrum and peaking in 2016 with 13.7. This trend coincided with late declining of esophageal biopsies rate. Overall prevalence in 2016 was 81.73 patients/100,000 inhabitants, with the highest prevalence in males between age 35 and 44 years (273 cases/100,000). No seasonal variation was observed in the diagnosis of EoE (53% during pollen season vs. 47%, p ¼ 0.4). Conclusions: In midwestern Spain, incidence (13.7 cases/100,000 inhabitants/year) and prevalence (81.73 patients/100,000 inhabitants) in 2016 have grown remarkably in just one decade, coming closer to those figures recently reported for Crohn's disease in Spain.

show abstract

Section: Discussionmentioning

confidence: 99%

Rising incidence and prevalence of adult eosinophilic esophagitis in midwestern Spain (2007–2016)

Molina–Infante

Gonzalez-Cordero

Ferreira-Nossa

et al. 2017

United European Gastroenterology Journal

View full text Add to dashboard Cite

show abstract

“…In Western Europe, North America and Oceania, the average age of onset in adult incident cases was a median 31–34 years . In both CD and UC, incidence peaked in the age interval 20–30 years; however, a second peak between the ages of 60–79 years was reported in UC.…”

Section: Clinical Features Of Ibdmentioning

confidence: 99%

The epidemiology of inflammatory bowel disease: East meets west

Mak

Zhao

et al. 2019

J of Gastro and Hepatol

370

247

View full text Add to dashboard Cite

The incidence of inflammatory bowel diseases (IBD) in East has risen over the past decade to become a global disease. The increasing number of studies on the incidence and course of IBD in East has enabled us to explore East versus West differences in the epidemiology of IBD which could enhance our understanding of the heterogeneity of the disease and eventually assist in the discovery of novel therapeutic targets and design of preventive strategies. Comparison of population‐based data in East and West reveals that the incidence of IBD has risen rapidly in East while plateauing in West. Furthermore, the clinical presentation and course of IBD differs between East and West with more patients in East presenting with complicated disease. Considering the scarcity of population‐based data from East and the lack of studies with long durations of follow‐up, it remains to be clarified whether these differences reflect true differences in disease presentation. The effects of genetic and environmental risk factors contributing to IBD also differ between Eastern and Western populations. Considering the differential effects of genetic and environmental risk factors in East and West, future studies should seek to discover novel genetic and environmental risk factors which might specifically apply to eastern populations. In this narrative review, we compare the epidemiology of IBD between eastern and western countries by summarizing evidence from population‐based cohort studies in the last ten years. Furthermore, we look at differences in genetic susceptibility and environmental triggers of IBD between East and West.

show abstract

“…Here we show that despite IBD being a worldwide chronic condition with increasing incidence [47,48] , there is a near complete absence in the literature of tools to assist primary care doctors in delivering appropriate, evidence-based care. This is in contrast to the situation…”

Section: Discussionmentioning

confidence: 99%

Tools for primary care management of inflammatory bowel disease: Do they exist?

Bennett

Munkholm

Andrews

2015

WJG

View full text Add to dashboard Cite

Healthcare systems throughout the world continue to face emerging challenges associated with chronic disease management. Due to the likely increase in chronic conditions in the future it is now vital that cooperation and support between specialists, generalists and primary health care physicians is conducted.Inflammatory bowel disease (IBD) is one such chronic disease. Despite specialist care being essential, much IBD care could and probably should be delivered in primary care with continued collaboration between all stakeholders. Whilst most primary care physicians only have few patients currently affected by IBD in their caseload, the proportion of patients with IBDrelated healthcare issues cared for in the primary care setting appears to be widespread. Data suggests however, that primary care physician's IBD knowledge and comfort in management is suboptimal. Current treatment guidelines for IBD are helpful but they are not designed for the primary care setting. Few nonexpert IBD management tools or guidelines exist compared with those used for other chronic diseases such as asthma and scant data have been published regarding the usefulness of such tools including IBD action plans and associated supportive literature. The purpose of this review is to investigate what nonspecialist tools, action plans or guidelines for IBD are published in readily searchable medical literature and compare these to those which exist for other chronic conditions. Core tip: Much inflammatory bowel disease (IBD) care could be delivered in the outpatient setting by primary care physicians. Whilst guidelines for IBD treatment exist, they are intended to support specialist practice and are not designed to use in the primary care setting. Our systematic reviewed found that a striking paucity of IBD outpatient supportive/educational tools for primary healthcare practitioners currently exists. This is despite good evidence of acceptability and usefulness of such tools in other chronic diseases. TOPIC HIGHLIGHT

show abstract

Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort

Abstract: Incidence rates, disease phenotype and initial treatment characteristics in the 2011 ECCO-EpiCom cohort were not significantly different from that reported in the 2010 cohort.

Cited by 85 publications

References 20 publications

Rising incidence and prevalence of adult eosinophilic esophagitis in midwestern Spain (2007–2016)

Rising incidence and prevalence of adult eosinophilic esophagitis in midwestern Spain (2007–2016)

The epidemiology of inflammatory bowel disease: East meets west

Tools for primary care management of inflammatory bowel disease: Do they exist?

Contact Info

Product

Resources

About